ALERE INC. Forms 3, 4 and 5: Restricted Stock Units and Performance Rights
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 53 rows in 2017. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-10-03: Reporting owner Wygant Jonathan; Form 4; Security Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2017-10-03: Reporting owner Uppaluri Renuka; Form 4; Security Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2017-10-03: Reporting owner Pelossof Avi; Form 4; Security Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2017-10-03: Reporting owner Nawana Namal; Form 4; Security Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-10-03 | Wygant Jonathan Officer (VP, Controller, CAO) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −6,666 0 owned after | no price filed | 2017-10-03 | |
| 2017-10-03 | Uppaluri Renuka Officer (Senior VP, Global R&D) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −22,991 0 owned after | no price filed | 2017-10-03 | |
| 2017-10-03 | Pelossof Avi Officer (GlobalPres, Infectious Disease) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −19,470 0 owned after | no price filed | 2017-10-03 | |
| 2017-10-03 | Nawana Namal Director, Officer (Chief Executive Officer) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −111,041 0 owned after | no price filed | 2017-10-03 | |
| 2017-10-03 | Nawana Namal Director, Officer (Chief Executive Officer) | 4 | Performance Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | no price filed | 2017-10-03 | |
| 2017-10-03 | Malkani Sanjay Officer (Global Pres., Toxicology) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −19,470 0 owned after | no price filed | 2017-10-03 | |
| 2017-10-03 | Hinrichs James F. Officer (Executive VP, CFO) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −44,350 0 owned after | no price filed | 2017-10-03 | |
| 2017-10-03 | Hargadon Robert Bernard Officer (SVP, Global Human Resources) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −16,324 0 owned after | no price filed | 2017-10-03 | |
| 2017-10-03 | Guerdan Melissa Officer (SVP, Global Quality & Reg.) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −19,470 0 owned after | no price filed | 2017-10-03 | |
| 2017-10-03 | Gladwell Mark Officer (Senior VP, Global Operations) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −16,324 0 owned after | no price filed | 2017-10-03 | |
| 2017-10-03 | Cramp Daniella Officer (Global Pres., Cardiometabolic) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −19,470 0 owned after | no price filed | 2017-10-03 | |
| 2017-10-03 | Chiniara Ellen Officer (GC, Chief Ethics Officer&Sec) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −19,470 0 owned after | no price filed | 2017-10-03 | |
| 2017-10-03 | BRIDGEN JOHN Officer (Sr VP, Business Development) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −16,324 0 owned after | no price filed | 2017-10-03 | |
| 2017-08-31 | Cramp Daniella Officer (Global Pres., Cardiometabolic) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,667 0 owned after | $48.14 exercise price | 2017-09-05 | |
| 2017-08-31 | BRIDGEN JOHN Officer (Sr VP, Business Develop) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 0 owned after | $0.00 | 2017-09-05 | |
| 2017-08-31 | Chiniara Ellen Officer (GC, Chief Ethics Officer&Sec) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,667 0 owned after | $0.00 | 2017-09-05 | |
| 2017-08-31 | Gladwell Mark Officer (Senior VP, Global Operations) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 0 owned after | $0.00 | 2017-09-05 | |
| 2017-08-31 | Guerdan Melissa Officer (SVP, Global Quality & Reg.) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,334 0 owned after | $0.00 | 2017-09-05 | |
| 2017-08-31 | Hargadon Robert Bernard Officer (SVP, Global Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,667 0 owned after | $0.00 | 2017-09-05 | |
| 2017-08-31 | Malkani Sanjay Officer (Global Pres., Toxicology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,667 0 owned after | $0.00 | 2017-09-05 | |
| 2017-08-31 | Pelossof Avi Officer (GlobalPres, Infectious Disease) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,667 0 owned after | $0.00 | 2017-09-05 | |
| 2017-06-30 | GOLDBERG CAROL R Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,530 0 owned after | $0.00 | 2017-07-05 | |
| 2017-06-30 | LEVY JOHN F Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,530 0 owned after | $0.00 | 2017-07-05 | |
| 2017-06-30 | MARKISON BRIAN A Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,530 0 owned after | $0.00 | 2017-07-05 | |
| 2017-06-30 | McKillop Thomas Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,530 0 owned after | $0.00 | 2017-07-05 | |
| 2017-06-30 | Powers Gregg J Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,530 0 owned after | $0.00 | 2017-07-05 | |
| 2017-06-30 | Ginsburg Geoffrey S Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,530 0 owned after | $0.00 | 2017-07-05 | |
| 2017-06-30 | QUELCH JOHN Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,530 0 owned after | $0.00 | 2017-07-05 | |
| 2017-06-30 | Roosevelt James Jr. Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,530 0 owned after | $0.00 | 2017-07-05 | |
| 2017-04-06 | Hinrichs James F. Officer (Executive VP, CFO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −16,667 16,667 owned after | $0.00 | 2017-04-10 | |
| 2017-02-28 | Uppaluri Renuka Officer (Senior VP, Global R&D) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,667 6,667 owned after | $0.00 | 2017-03-02 | |
| 2017-02-16 | Uppaluri Renuka Officer (Senior VP, Global R&D) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Uppaluri Renuka Officer (Senior VP, Global R&D) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,663 11,324 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Pelossof Avi Officer (GlobalPres, Infectious Disease) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Pelossof Avi Officer (GlobalPres, Infectious Disease) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,236 14,470 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Nawana Namal Director, Officer (Chief Executive Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −47,188 94,374 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Malkani Sanjay Officer (Global Pres., Toxicology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Malkani Sanjay Officer (Global Pres., Toxicology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,236 14,470 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Hinrichs James F. Officer (Executive VP, CFO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,842 27,683 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Hargadon Robert Bernard Officer (SVP, Global Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Hargadon Robert Bernard Officer (SVP, Global Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,663 11,324 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Guerdan Melissa Officer (SVP, Global Quality & Reg.) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Guerdan Melissa Officer (SVP, Global Quality & Reg.) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,236 14,470 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Gladwell Mark Officer (Senior VP, Global Operations) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Gladwell Mark Officer (Senior VP, Global Operations) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,663 11,324 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Cramp Daniella Officer (Global Pres., Cardiometabolic) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Cramp Daniella Officer (Global Pres., Cardiometabolic) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,236 14,470 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Chiniara Ellen Officer (GC, Chief Ethics Officer&Sec) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | Chiniara Ellen Officer (GC, Chief Ethics Officer&Sec) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,236 14,470 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | BRIDGEN JOHN Officer (Sr VP, Business Develop) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | 2017-02-21 | |
| 2017-02-16 | BRIDGEN JOHN Officer (Sr VP, Business Develop) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,663 11,324 owned after | $0.00 | 2017-02-21 | |
| 2017-01-15 | Nawana Namal Director, Officer (Chief Executive Officer) | 4 | Performance Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 50,000 owned after | $0.00 | 2017-06-16 | |
| 2017-01-15 | Wygant Jonathan Officer (VP, Controller, CAO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,334 6,666 owned after | $0.00 | 2017-01-17 |